Cargando…

MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

SIMPLE SUMMARY: CA27.29 (MUC1) is a well described biomarker for prediction of prognosis and treatment efficacy. CA27.29 is mainly evaluated in the preoperative setting. However, testing of postoperative levels and additional assessment after chemotherapy might be more informative for analyzing the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huebner, Hanna, Häberle, Lothar, Müller, Volkmar, Schrader, Iris, Lorenz, Ralf, Forstbauer, Helmut, Fink, Visnja, Schochter, Fabienne, Bekes, Inga, Mahner, Sven, Jückstock, Julia, Nabieva, Naiba, Schneeweiss, Andreas, Tesch, Hans, Brucker, Sara Y., Blohmer, Jens-Uwe, Fehm, Tanja N., Heinrich, Georg, Rezai, Mahdi, Beckmann, Matthias W., Fasching, Peter A., Janni, Wolfgang, Rack, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997086/ https://www.ncbi.nlm.nih.gov/pubmed/35406491 http://dx.doi.org/10.3390/cancers14071721

Ejemplares similares

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
por: de Gregorio, Amelie, et al.
Publicado: (2020)

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
por: Wöckel, Achim, et al.
Publicado: (2018)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
por: Janni, Wolfgang, et al.
Publicado: (2019)

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial
por: Jueckstock, Julia, et al.
Publicado: (2016)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Nabieva, Naiba, et al.
Publicado: (2021)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial
por: Trapp, Elisabeth K., et al.
Publicado: (2022)

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
por: Rack, Brigitte, et al.
Publicado: (2014)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Editorial for the Special Issue “Breast Cancer—Therapeutic Challenges, Research Strategies and Novel Diagnostics”
por: Nabieva, Naiba
Publicado: (2023)

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity
por: Fasching, Peter A., et al.
Publicado: (2017)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients
por: Alunni-Fabbroni, Marianna, et al.
Publicado: (2018)

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians
por: Gass, Paul, et al.
Publicado: (2018)

VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment
por: Karsten, Maria Margarete, et al.
Publicado: (2020)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Effect of an Augmented Reality Ultrasound Trainer App on the Motor Skills Needed for a Kidney Ultrasound: Prospective Trial
por: Ebner, Florian, et al.
Publicado: (2019)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
por: Schochter, Fabienne, et al.
Publicado: (2020)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses
por: Heitmeir, Benedikt, et al.
Publicado: (2022)

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
por: Schneeweiss, Andreas, et al.
Publicado: (2021)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Return of individual genomic research results within the PRAEGNANT multicenter registry study
por: Huebner, Hanna, et al.
Publicado: (2022)

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
por: Jaeger, B. A. S., et al.
Publicado: (2017)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

2729. mRNA Vaccines Encoding Conserved Influenza Antigens Induce Robust and Durable Immunity in Rhesus Macaques
por: Flynn, Jessica, et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

C2729T mutation associated with HBV mother-to-child transmission reduces HBV production via suppressing LHBs expression
por: Liu, Minmin, et al.
Publicado: (2023)

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
por: Schochter, Fabienne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_isih0l4g0l6uij67fmgpkasmnm